CApecitabine plus Radium-223 (Xofigo ™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial

DiscussionThe CARBON study is important as the results will be the first to assess radium-223 with chemotherapy in advanced breast cancer. If the results find acceptable rates of toxicity with a decrease in bone turnover markers, further work will be necessary in a phase II/III setting to assess the efficacy and clinical benefit.Trial registrationISRCTN,ISRCTN92755158, Registered on 17 February 2016.
Source: Trials - Category: Research Source Type: clinical trials